Response to anti-IL17 therapy in inflammatory disease is not strongly impacted by genetic background

Response to the anti-IL17 monoclonal antibody secukinumab is heterogeneous, and not all participants respond to treatment. Understanding whether this heterogeneity is driven by genetic variation is a key aim of pharmacogenetics and could influence precision medicine approaches in inflammatory diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Cong, Shestopaloff, Konstantin, Hollis, Benjamin, Kwok, Chun Hei, Hon, Claudia, Hartmann, Nicole, Tian, Chengeng, Wozniak, Magdalena, Santos, Luis, West, Dominique, Gardiner, Stephen, Mallon, Ann-Marie, Readie, Aimee, Martin, Ruvie, Nichols, Thomas, Beste, Michael T., Zierer, Jonas, Ferrero, Enrico, Vandemeulebroecke, Marc, Jostins-Dean, Luke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577077/
https://www.ncbi.nlm.nih.gov/pubmed/37659414
http://dx.doi.org/10.1016/j.ajhg.2023.08.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577077/
https://www.ncbi.nlm.nih.gov/pubmed/37659414
http://dx.doi.org/10.1016/j.ajhg.2023.08.010

Ejemplares similares